Back to today’s briefing

Story perspectives

New Strategies to Lower Cardiovascular Risks and Toilet Blockages

6/3/2025

29 6

Summary

Story summary

Elevated Lp(a) levels heighten cardiovascular risk, leading to aspirin therapy (100 mg/day) for at-risk patients.
Cardiologists recommend PCSK9 inhibitors, such as alirocumab and evolocumab, to reduce Lp(a) levels.
Toilet design challenges stem from different stool bulk; wider trapways and stronger flushes may improve functionality.
High-fiber diets and double-flushing methods can effectively reduce toilet blockages.

1 of 1

Story summary

Elevated Lp(a) levels heighten cardiovascular risk, leading to aspirin therapy (100 mg/day) for at-risk patients.
Cardiologists recommend PCSK9 inhibitors, such as alirocumab and evolocumab, to reduce Lp(a) levels.
Toilet design challenges stem from different stool bulk; wider trapways and stronger flushes may improve functionality.
High-fiber diets and double-flushing methods can effectively reduce toilet blockages.